ArticleJournal of applied toxicology : JAT2014
A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.
Article in Journal of applied toxicology : JAT, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Hair, serum and urine chromium levels in children with cognitive defects: A systematic review and meta-analysis of case control studies.Chemosphere · 2022Pooled it
- Multivariate statistical evaluation of heavy metals in the urine of opium individuals in comparison with healthy people in Western Iran.Environmental science and pollution research international · 2022Article
- Highly Luminescent Nucleoside-Based N, P-Doped Carbon Dots for Sensitive Detection of Ions and Bioimaging.Frontiers in chemistry · 2022Article
- Enrichment Characteristics of Cr in Chromium Slag after Pre-Reduction and Melting/Magnetic Separation Treatment.Materials (Basel, Switzerland) · 2021Article
- Leaching of Valuable Elements from the Waste Chromite Ore Processing Residue: A Kinetic Analysis.ACS omega · 2020Article
- A Novel Transcriptome Integrated Network Approach Identifies the Key Driver lncRNA Involved in Cell Cycle With Chromium (VI)-Treated BEAS-2B Cells.Frontiers in genetics · 2020Article
- DNA methylation modifications induced by hexavalent chromium.Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews · 2019Article
- Occurrence of bacterial and toxic metals contamination in illegal opioid-like drugs in Iran: a significant health challenge in drug abusers.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018Article
- Luminescent Lanthanide MOFs: A Unique Platform for Chemical Sensing.Materials (Basel, Switzerland) · 2018Review
- A series of LnRSC advances · 2018Article
- Effects of chromium picolinate on fat deposition, activity and genetic expression of lipid metabolism-related enzymes in 21 day old Ross broilers.Asian-Australasian journal of animal sciences · 2018Article
- Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium.Journal of applied toxicology : JAT · 2018Article
- Biomarkers of oxidative stress in electroplating workers exposed to hexavalent chromium.Journal of exposure science & environmental epidemiology · 2018Article
- Comparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium.Toxicologic pathology · 2017Article
- CoQ10 Deficiency May Indicate Mitochondrial Dysfunction in Cr(VI) Toxicity.International journal of molecular sciences · 2017Article
- An evaluation of the protective role of vitamin C in reactive oxygen species-induced hepatotoxicity due to hexavalent chromium in vitro and in vivo.Journal of occupational medicine and toxicology (London, England) · 2017Article
- Carcinogenicity of chromium and chemoprevention: a brief update.OncoTargets and therapy · 2017Review
- Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.Environmental and molecular mutagenesis · 2016Article
- Different roles of ROS and Nrf2 in Cr(VI)-induced inflammatory responses in normal and Cr(VI)-transformed cells.Toxicology and applied pharmacology · 2016Article
- Reevaluation and Classification of Duodenal Lesions in B6C3F1 Mice and F344 Rats from 4 Studies of Hexavalent Chromium in Drinking Water.Toxicologic pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High concentrations of hexavalent chromium [Cr(VI)] in drinking water induce villous cytotoxicity and compensatory crypt hyperplasia in the small intestines of mice (but not rats). Lifetime exposure to such cytotoxic concentrations increases intestinal neoplasms in mice, suggesting that the mode of action for Cr(VI)-induced intestinal tumors involves chronic wounding and compensatory cell proliferation of the intestine. Therefore, we developed a chronic oral reference dose (RfD) designed to be protective of intestinal damage and thus intestinal cancer. A physiologically based pharmacokinetic model for chromium in mice was used to estimate the amount of Cr(VI) entering each intestinal tissue section (duodenum, jejunum and ileum) from the lumen per day (normalized to intestinal tissue weight). These internal dose metrics, together with corresponding incidences for diffuse hyperplasia, were used to derive points of departure using benchmark dose modeling and constrained nonlinear regression. Both modeling techniques resulted in similar points of departure, which were subsequently converted to human equivalent doses using a human physiologically based pharmacokinetic model. Applying appropriate uncertainty factors, an RfD of 0.006 mg kg(-1) day(-1) was derived for diffuse hyperplasia-an effect that precedes tumor formation. This RfD is protective of both noncancer and cancer effects in the small intestine and corresponds to a safe drinking water equivalent level of 210 µg l(-1). This concentration is higher than the current federal maximum contaminant level for total Cr (100 µg l(-1)) and well above levels of Cr(VI) in US drinking water supplies (typically ≤ 5 µg l(-1)).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.